Hendrikse H - Search Results

1

EANM position on the in-house preparation of radiopharmaceuticals.

Hendrikse H, Kiss O, Kunikowska J, Wadsak W, Decristoforo C, Patt M. Hendrikse H, et al. Eur J Nucl Med Mol Imaging. 2022 Mar;49(4):1095-1098. doi: 10.1007/s00259-022-05694-z. Eur J Nucl Med Mol Imaging. 2022. PMID: 35050391

2

Prospective analysis of clinically significant prostate cancer detection with [¹⁸F]DCFPyL PET/MRI compared to multiparametric MRI: a comparison with the histopathology in the radical prostatectomy specimen, the ProStaPET study.

Bodar YJL, Zwezerijnen BGJC, van der Voorn PJ, Jansen BHE, Smit RS, Kol SQ, Meijer D, de Bie K, Yaqub M, Windhorst BAD, Hendrikse HNH, Vis AN, Oprea-Lager DE. Bodar YJL, et al. Among authors: hendrikse hnh. Eur J Nucl Med Mol Imaging. 2022 Apr;49(5):1731-1742. doi: 10.1007/s00259-021-05604-9. Epub 2021 Nov 2. Eur J Nucl Med Mol Imaging. 2022. PMID: 34725727 Free PMC article.

3

Applying quality by design principles to the small-scale preparation of the bone-targeting therapeutic radiopharmaceutical rhenium-188-HEDP.

Lange R, Ter Heine R, van der Gronde T, Selles S, de Klerk J, Bloemendal H, Hendrikse H. Lange R, et al. Among authors: hendrikse h. Eur J Pharm Sci. 2016 Jul 30;90:96-101. doi: 10.1016/j.ejps.2016.01.008. Epub 2016 Jan 7. Eur J Pharm Sci. 2016. PMID: 26772897

4

Identifying advanced stage NSCLC patients who benefit from afatinib therapy using ¹⁸F-afatinib PET/CT imaging.

van de Stadt EA, Yaqub M, Lammertsma AA, Poot AJ, Schuit RC, Remmelzwaal S, Schwarte LA, Smit EF, Hendrikse H, Bahce I. van de Stadt EA, et al. Among authors: hendrikse h. Lung Cancer. 2021 May;155:156-162. doi: 10.1016/j.lungcan.2021.03.016. Epub 2021 Mar 26. Lung Cancer. 2021. PMID: 33836373 Free article.

5

Predicting early outcomes in patients with intermediate- and high-risk prostate cancer using prostate-specific membrane antigen positron emission tomography and magnetic resonance imaging.

Meijer D, van Leeuwen PJ, Donswijk ML, Boellaard TN, Schoots IG, van der Poel HG, Hendrikse HN, Oprea-Lager DE, Vis AN. Meijer D, et al. Among authors: hendrikse hn. BJU Int. 2022 Jan;129(1):54-62. doi: 10.1111/bju.15492. Epub 2021 Jun 16. BJU Int. 2022. PMID: 34028165 Free PMC article.

6

Relationship between Biodistribution and Tracer Kinetics of ¹¹C-Erlotinib, ¹⁸F-Afatinib and ¹¹C-Osimertinib and Image Quality Evaluation Using Pharmacokinetic/Pharmacodynamic Analysis in Advanced Stage Non-Small Cell Lung Cancer Patients.

van de Stadt EA, Yaqub M, Schuit RC, Bartelink IH, Leeuwerik AF, Schwarte LA, de Langen AJ, Hendrikse H, Bahce I. van de Stadt EA, et al. Among authors: hendrikse h. Diagnostics (Basel). 2022 Apr 1;12(4):883. doi: 10.3390/diagnostics12040883. Diagnostics (Basel). 2022. PMID: 35453931 Free PMC article.

7

Erratum to "Pharmaceutical and clinical development of phosphonate-based radiopharmaceuticals for the targeted treatment of bone metastases" [Bone 91 (2016) 159-179].

Lange R, Ter Heine R, Knapp RF, de Klerk JMH, Bloemendal HJ, Hendrikse HN. Lange R, et al. Among authors: hendrikse hn. Bone. 2017 Dec;105:315. doi: 10.1016/j.bone.2016.11.023. Epub 2016 Nov 30. Bone. 2017. PMID: 27914925 No abstract available.

8

In vivo delineation of 5-HT1A receptors in human brain with [18F]MPPF.

Passchier J, van Waarde A, Pieterman RM, Elsinga PH, Pruim J, Hendrikse HN, Willemsen AT, Vaalburg W. Passchier J, et al. Among authors: hendrikse hn. J Nucl Med. 2000 Nov;41(11):1830-5. J Nucl Med. 2000. PMID: 11079490 Free article.

9

PET Imaging and Protein Expression of Prostate-Specific Membrane Antigen in Glioblastoma: A Multicenter Inventory Study.

van Lith SAM, Pruis IJ, Tolboom N, Snijders TJ, Henssen D, Ter Laan M, Te Dorsthorst M, Leenders WPJ, Gotthardt M, Nagarajah J, Robe PA, De Witt Hamer P, Hendrikse H, Oprea-Lager DE, Yaqub M, Boellaard R, Wesseling P, Balvers RK, Verburg FA, Harteveld AA, Smits M, van den Bent M, van Zanten SEMV, van de Giessen E. van Lith SAM, et al. Among authors: hendrikse h. J Nucl Med. 2023 Oct;64(10):1526-1531. doi: 10.2967/jnumed.123.265738. Epub 2023 Aug 31. J Nucl Med. 2023. PMID: 37652540

10

Radiolabeled EGFR TKI as predictive imaging biomarkers in NSCLC patients - an overview.

Van De Stadt E, Yaqub M, Jahangir AA, Hendrikse H, Bahce I. Van De Stadt E, et al. Among authors: hendrikse h. Front Oncol. 2022 Oct 12;12:900450. doi: 10.3389/fonc.2022.900450. eCollection 2022. Front Oncol. 2022. PMID: 36313723 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

22 results

Search Page